Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Apr;17(4):545-547.
doi: 10.1002/1878-0261.13413. Epub 2023 Mar 17.

The interplay between eosinophils and T cells in breast cancer immunotherapy

Ioannis Zerdes  1   2 , Alexios Matikas  1   2 , Theodoros Foukakis  1   2
Affiliations
Comment

The interplay between eosinophils and T cells in breast cancer immunotherapy

Ioannis Zerdes et al. Mol Oncol. 2023 Apr.

Abstract

Treatment with immune checkpoint inhibitors (ICI) has revolutionized cancer management for multiple tumor types, including breast cancer. However, not all patients respond to ICI, and unraveling the determinants and mechanisms of response still remains an unmet need. A recent study has uncovered the critical role of eosinophils in mediating immunotherapy effect in breast cancer, mainly by stimulating the activation of CD8+ T-cells. Furthermore, the intratumoral eosinophil recruitment was directed by CD4+ T cells and the interleukins IL-5 and IL-33, thus providing the rationale for targeting eosinophils to enhance ICI response.

Keywords: T cells; breast cancer; eosinophils; immunotherapy; tumor microenvironment.

PubMed Disclaimer

Conflict of interest statement

Ioannis Zerdes has no conflict of interest to declare. Alexios Matikas: consultancy to Veracyte (no financial or other compensation) and Roche (no financial or other compensation). Theodoros Foukakis: consultancy to Astra Zeneca, Affibody, Pfizer, Novartis, Veracyte, Exact Sciences, Gilead Sciences and Roche; honoraria from UpToDate; research funding to institution from Pfizer, Astra Zeneca, and Novartis.

Comment on

References

    1. Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple‐negative breast cancer (KEYNOTE‐355): a randomised, placebo‐controlled, double‐blind, phase 3 clinical trial. Lancet. 2020;396:1817–28. - PubMed
    1. Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab plus nab‐paclitaxel as first‐line treatment for unresectable, locally advanced or metastatic triple‐negative breast cancer (IMpassion130): updated efficacy results from a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Oncol. 2020;21:44–59. - PubMed
    1. Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, et al. Pembrolizumab for early triple‐negative breast cancer. N Engl J Med. 2020;382:810–21. - PubMed
    1. Kossai M, Radosevic‐Robin N, Penault‐Llorca F. Refining patient selection for breast cancer immunotherapy: beyond PD‐L1. ESMO Open. 2021;6:100257. - PMC - PubMed
    1. Barroso‐Sousa R, Keenan TE, Pernas S, Exman P, Jain E, Garrido‐Castro AC, et al. Tumor mutational burden and PTEN alterations as molecular correlates of response to PD‐1/L1 blockade in metastatic triple‐negative breast cancer. Clin Cancer Res. 2020;26:2565–72. - PMC - PubMed

Publication types